KIR2DS5 allotypes that recognize the C2 epitope of HLA‐C are common among Africans and absent from Europeans. Issue 4 (6th July 2017)

• Record Type: Journal Article
• Authors: Blokhuis, Jeroen H.; Hilton, Hugo G.; Guethlein, Lisbeth A.; Norman, Paul J.; Nemat‐Gorgani, Neda; Nakimuli, Annettee; Chazara, Olympe; Moffett, Ashley; Parham, Peter
• Is Part Of: Immunity, inflammation and disease. Volume 5:Issue 4(2017)
• Page Start: 461
• Page End: 468
• Publication Date: 2017-07-06
• Subjects: Africa -- HLA‐C -- KIR -- NK cells -- pregnancy; Immunology -- Periodicals; Immunity -- Periodicals; Inflammation -- Periodicals; 616.079
• DOI: 10.1002/iid3.178
• Languages: English
• ISSNs: 2050-4527

Abstract

Abstract: Introduction: KIR2DS5 is an activating human NK cell receptor of lineage III KIR. These include both inhibitory KIR2DL1, 2 and 3 and activating KIR2DS1 that recognize either the C1 or C2 epitope of HLA‐C. In Europeans KIR2DS5 is essentially monomorphic, with KIR2DS5*002 being predominant. Pioneering investigations showed that KIR2DS5*002 has activating potential, but cannot recognize HLA‐A, ‐B, or ‐C. Subsequent studies have shown that KIR2DS5 is highly polymorphic in Africans, and that KIR2DS5*006 protects pregnant Ugandan women from preeclampsia. Because inhibitory C2‐specific KIR2DL1 correlates with preeclampsia, whereas activating C2‐specific KIR2DS1 protects, this association pointed to KIR2DS5*006 being an activating C2‐specific receptor. To test this hypothesis we made KIR‐Fc fusion proteins from all ten KIR2DS5 allotypes and tested their binding to a representative set of HLA‐A, ‐B and ‐C allotypes. Results: Six African‐specific KIR2DS5 bound to C2 + HLA‐C but not to other HLA class I. Their avidity for C2 is ∼20% that of C2‐specific KIR2DL1 and ∼40% that of C2‐specific KIR2DS1. Among the African C2 receptors is KIR2DS5*006, which protected a cohort of pregnant Ugandans from pre‐eclampsia. Three African KIR2DS5 allotypes and KIR2DS5*002, bound no HLA‐A, ‐B or ‐C. As a group the C2‐binding KIR2DS5 allotypes protect against pre‐eclampsia compared to the non‐binding KIR2DS5 allotypes. Natural substitutions that contribute to loss or reduction of C2 receptor function are at positions 127, 158, and 176 in the D2 domain. Conclusions: KIR2DS5*005 has the KIR2DS5 consensus sequence, is the only allele found at both centromeric and telomeric locations of KIR2DS5, and is likely the common ancestor of all KIR2DS5 alleles. That KIR2DS5*005 has C2 receptor activity, points to KIR2DS5*002, and other allotypes lacking C2 receptor function, being products of attenuation, a characteristic feature of most KIR B haplotype genes. Alleles encoding attenuated and active KIR2DS5 are present in both centromeric and telomeric locations. Abstract : In Africans KIR2DS5 is highly polymorphic and KIR2DS5*006 is known to protect pregnant women from preeclampsia. Of ten KIR2DS5 tested, KIR2DS5*006 and five other allotypes recognize the C2 epitope of HLA‐C, whereas four allotypes have no detectable affinity for HLA class I. In the latter group is KIR2DS5*002, the form of KIR2DS5 that is dominant in European populations.